AB Science a reçu les premières autorisations règlementaires pour initier une étude clinique confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer
October 10, 2022 12:04 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A REÇU LES PREMIÈRES AUTORISATIONS RÈGLEMENTAIRES POUR INITIER UNE ÉTUDE CLINIQUE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA MALADIE...
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
October 10, 2022 12:04 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm...
Global Extracorporeal Membrane Oxygenation System Market to Surpass US$ 476.8 Million by 2030, Says Coherent Market Insights (CMI)
July 12, 2022 09:10 ET
|
CMI
Seattle, July 12, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global extracorporeal membrane oxygenation system market is estimated to be valued at US$ 316.5 million in 2022...
Eventa LLC Welcomes Michelle Harrison as Director of Business
June 17, 2022 09:00 ET
|
Eventa LLC
LIVINGSTON, Tenn., June 17, 2022 (GLOBE NEWSWIRE) -- Eventa LLC, leading experts in post-acute respiratory care, complex airway care, long-term ventilation and liberation, welcomes Michelle Harrison...
North America Precision Medicine Market size to surpass $50bn by 2027, says Graphical Research
May 02, 2022 07:07 ET
|
Graphical Research
Pune, India, May 02, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the North America precision medicine market is forecast to register its name in the...
爱科百发宣布爱司韦™在治疗呼吸道合胞病毒（RSV）感染的住院婴幼儿中的临床三期试验达到主要终点
April 07, 2022 03:50 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
在临床三期AirFLO试验中，爱司韦™与安慰剂相比显著降低症状评分（p=0.002）及病毒载量（p=0.006），达到试验主要终点和关键次要终点 RSV感染是五岁以下儿童因病毒感染而住院及死亡的首要因素爱司韦™是全球首个成功在儿童患者人群中完成关键性三期临床研究的RSV抗病毒药物爱司韦™计划于2022年年中向中国监管机构提交新药上市申请 上海, April 07, 2022 (GLOBE...
愛科百發宣佈愛司韋™在治療呼吸道合胞病毒（RSV）感染的住院嬰幼兒中的臨床三期試驗達到主要終點
April 07, 2022 03:50 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
在臨床三期AirFLO試驗中，愛司韋™與安慰劑相比顯著降低症狀評分（p=0.002）及病毒載量（p=0.006），達到試驗主要終點和關鍵次要終點 RSV感染是五歲以下兒童因病毒感染而住院及死亡的首要因素愛司韋™是全球首個成功在兒童患者人群中完成關鍵性三期臨床研究的RSV抗病毒藥物愛司韋™計畫於2022年年中向中國監管機構提交新藥上市申請 上海, April 07, 2022 ...
ArkBio Announces Positive Results of Phase 3 Study with Ziresovir in Infants and Children Hospitalized with Respiratory Syncytial Virus Infection
April 07, 2022 03:50 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3 AirFLO study with ziresovir met primary and key secondary endpoints of significant reduction of sign-and-symptom score (p=0.002) and viral load (p=0.006) respectively, compared with...
Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce
March 14, 2022 02:15 ET
|
Novartis Pharma AG
Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading...
Lungpacer Medical Accelerates Pivotal Clinical Study with AeroPace™ System
February 14, 2022 11:49 ET
|
Lungpacer Medical USA Inc.
EXTON, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace™ System, a next generation product,...